KLK3 and Familial prostate cancer: PSA-specific CTL-mediated approaches developed to therapeutically treat prostate cancer have shown efficacy in the clinic and provided the rationale for development of an Lm-based vaccine targeting PSA, Lm-LLO-PSA (Heiser et al., 2002; Shahabi et al., 2008).